MRI in High-Grade Glioma Patients Undergoing Chemoradiation
ConditionHigh Grade Glioma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorWake Forest University Health Sciences
About this trial
The purpose of this research study is to see if investigators can predict how brain functioning changes after radiation treatment based on PET scans and blood tests. Most participants experience at least mild decreases in their memory or attention after radiation therapy. Investigators hope that PET scans, optional lumbar puncture, and blood tests might help investigators predict who might have larger changes in their brain function after radiation.
Eligibility criteria
Qualifiers
Pathologically confirmed diagnosis of high-grade glioma (grade III or IV) or WHO grade II glioma, IDH wildtype (molecular glioblastoma multiforme [GBM]).
≥18 years of age.
ECOG performance status of 0 to 3
Anticipated to receive 6 weeks of chemoradiation
Disqualifiers
Does not speak or read English
Unable to participate in cognitive testing due to aphasia or other severe cognitive impairment as determined by the PI, or Dr. Cummings or her designee.
Unable to give informed consent
Past medical history of any kind of dementia or diagnosed with mild cognitive impairment prior to diagnosis with their brain tumor
Trial design
Treatments tested in this trial
- PET-MRI Brain Scan
- Blood draw
- Memory testing
- Optional lumbar puncture for cerebrospinal fluid collection
Treatment groups
16 Participants
are divided into 1 treatment groupSponsors and collaborators
Wake Forest University Health Sciences
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov